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Abstract
IMPORTANCE Squamous cell carcinoma (SCC) of the oral cavity is one of the most common tumor
entities worldwide. Precise initial staging is necessary to determine a diagnosis, treatment, and
prognosis.
OBJECTIVE To examine the diagnostic accuracy of preoperative 18-F fluorodeoxyglucose (FDG)
positron emission tomographic/computed tomographic (PET/CT) imaging in detecting cervical
lymph node metastases.
DESIGN, SETTING, AND PARTICIPANTS This prospective diagnostic study was performed at a
single tertiary reference center between June 1, 2013, and January 31, 2016. Data were analyzed from
April 7, 2018, through May 31, 2019. Observers of the FDG PET/CT imaging were blinded to patients’
tumor stage. A total of 150 treatment-naive patients with clinical suspicion of SCC of the oral cavity
were enrolled.
EXPOSURES All patients underwent FDG PET/CT imaging before local tumor resection with
selective or complete neck dissection.
MAIN OUTCOMES AND MEASURES The accuracy of FDG PET/CT in localizing primary tumor,
lymph node, and distant metastases was tested. Histopathologic characteristics of the tissue samples
served as the standard of reference.
RESULTS Of the 150 patients enrolled, 135 patients (74 [54.8%] men) with a median age of 63 years
(range, 23-88 years) met the inclusion criteria (histopathologically confirmed primary SCC of the oral
cavity/level-based histopathologic assessment of the resected lymph nodes). Thirty-six patients
(26.7%) in the study cohort had neck metastases. Use of FDG PET/CT detected cervical lymph node
metastasis with 83.3% sensitivity (95% CI, 71.2%-95.5%) and 84.8% specificity (95% CI,
77.8%-91.9%) and had a negative predictive value of 93.3% (95% CI, 88.2%-98.5%). The specificity
was higher than for contrast-enhanced cervical CT imaging (67.0%; 95% CI, 57.4%-76.7%; P < .01)
and cervical magnetic resonance imaging (62.6%; 95% CI, 52.7%-72.6%; P < .001). Ipsilateral lymph
node metastasis in left- or right-sided primary tumor sites was detected with 78.6% sensitivity (95%
CI, 63.4%-93.8%) and 83.1% specificity (95% CI, 75.1%-91.2%), and contralateral metastatic
involvement was detected with 66.7% sensitivity (95% CI, 28.9%-100.0%) and 98.6% specificity
(95% CI, 95.9%-100.0%). No distant metastases were observed.
(continued)
Key Points
Question What is the diagnostic
accuracy of 18-F fluorodeoxyglucose
positron emission tomographic/
computed tomographic imaging in
squamous cell carcinoma of the oral
cavity for detection of metastases?
Findings This diagnostic study
including 135 patients showed 83.3%
sensitivity, 84.8% specificity, and a
negative predictive value of 93.3% with
use of 18-F fluorodeoxyglucose positron
emission tomographic/computed
tomographic imaging for detecting
cervical lymph node metastases. The
specificity was significantly higher than
observed for use of cervical computed
tomography and magnetic
resonance imaging.
Meaning Owing to its high negative
predictive value, preoperative 18-F
fluorodeoxyglucose positron emission
tomographic/computed tomographic
imaging may be useful to prevent
overtreatment in more than 70% of
patients with category T1 to T4 tumors
of the oral cavity.
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Abstract (continued)
CONCLUSIONS AND RELEVANCE In this study, FDG PET/CT imaging had a high negative predictive
value in detecting cervical lymph node metastasis in patients with newly diagnosed, treatment-
naive SCC of the oral cavity. Routine clinical use of FDG PET/CT might lead to a substantial reduction
of treatment-related morbidity in most patients.
JAMA Network Open. 2021;4(4):e217083. doi:10.1001/jamanetworkopen.2021.7083
Introduction
Cancer of the oral cavity and the oropharynx is the sixth most common tumor entity and the ninth
most frequent cause of death worldwide.1,2 The annual estimated incidence of squamous cell
carcinoma (SCC) of the oral cavity is approximately 275 000, and these cases represent more than
90% of all oral cancers.3,4 However, the diagnosis is determined late in up to 50% of patients and
thus the condition is associated with a poor prognosis; the survival rate is approximately 60%, and
the estimated recurrence rate is approximately 30% at 5-year follow-up.5,6 The presence of cervical
lymph node metastasis is one of the most important adverse prognostic factors.7-10 Distant
metastases, although rare, are generally considered incurable and therefore alter the
therapeutic regimen.11
Precise initial tumor staging is necessary to determine a diagnosis, treatment, and prognosis.
This staging requires accurate detection of (1) the primary tumor (T), (2) cervical lymph nodal
involvement (N), and (3) distant metastases (M).12,13 In addition to a clinical examination, established
imaging techniques for primary staging include ultrasonography, computed tomography (CT), and
magnetic resonance imaging (MRI).14,15 Despite improvements in imaging, the overall rate of occult
(clinically and radiologically undetectable) metastases in SCC of the oral cavity is approximately 15%
to 34%.1,16-19 Selective neck dissection thus maximizes survival probability but leads to
overtreatment, which is accompanied by reduced quality of life in approximately 75% of patients.20
Preoperative whole-body screening methods with a reliable prediction of N0 status of necks might
help to reduce this rate. The value of positron emission tomography (PET) with 18-F
fluorodeoxyglucose (FDG) in the preoperative staging of head and neck SCC has been demonstrated
in the literature.21-26 However, only a few prospective studies that used FDG PET/CT imaging in
cohorts with SCC of the oral cavity have thus far been conducted.24,27 A 2019 multicenter study
obtained a high negative predictive value of FDG PET/CT in clinically noted N0 status of the neck
sides of patients with head and neck SCC after imaging via MRI and/or CT.28 However, the
preselection used in the study impedes general conclusions as to the diagnostic accuracy of FDG
PET/CT and does not reveal whether this procedure can replace stand-alone morphologic imaging.
The aim of the present study was therefore to prospectively examine the diagnostic accuracy of
FDG PET/CT in detecting cervical lymph node metastasis in patients with newly diagnosed SCC of
the oral cavity who are treatment-naive. Particular importance was given to the negative predictive
value of FDG PET/CT and to detecting lymph node metastases based on their localization ipsilateral
or contralateral to the primary tumor site. We furthermore compared the diagnostic measures of
FDG PET/CT with those of both cervical MRI and contrast-enhanced CT in the study cohort. In
addition, we report on the detection rate of FDG PET/CT with regard to second primary tumors.
Methods
Study Design and Patients
From June 1, 2013, to January 31, 2016, a total of 150 patients with clinical suspicion of SCC of the oral
mucosa were prospectively enrolled. Whole-body FDG PET/CT and cervical MRI were performed
before further invasive interventions (panendoscopy and/or acquisition of biopsy samples). All
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patients underwent surgery within 2 weeks of the imaging workup. Resected primary tumors and
lymph nodes were histopathologically evaluated. Data were analyzed from April 7, 2018, through
May 31, 2019. The institutional review board of the University Hospital of Würzburg, Würzburg,
Germany, approved this study, and written, informed consent was obtained from all participants. This
study followed the Standards for Reporting of Diagnostic Accuracy (STARD) reporting guideline for
diagnostic studies.29
The inclusion criteria for this study were defined as no previous treatment, histopathologically
confirmed primary SCC of the oral cavity, and a level-based histopathologic assessment of resected
lymph nodes. Patients with (1) tumor relapse, (2) cancer of unknown primary site, (3) en bloc
resection of lymph node levels, or (4) uncertainties regarding the removed lymph node levels were
excluded.
Imaging
Imaging for all patients was performed on an integrated PET/CT scanner (Siemens Biograph mCT 64;
Siemens Healthineers). Before imaging, patients fasted for at least 4 to 6 hours. Blood glucose levels
were measured and confirmed to be below 160 mg/dL (to convert to millimoles per liter, multiply by
0.0555) before the intravenous injection of FDG, 300 ± 25 megabecquerels. After a distribution
period of 60 minutes, PET emission data were acquired in 3-dimensional mode with a 200 × 200
matrix with 2-minute emission time per bed position from the vertex of the skull to the proximal
thighs. Consecutively, transmission data were acquired using contrast-enhanced spiral CT (dose
modulation with a quality reference of 180 mA per second, 120 kV, a 512 × 512 matrix, 5-mm slice
thickness, an increment of 30 mm/s, a rotation time of 0.5 seconds, and a pitch index of 1.4).
Furthermore, a dedicated acquisition of the head and neck with 1 bed position, a 3-minute emission
time, and a contrast-enhanced CT was performed (180 mA per second, 120 kV, a 512 × 512 matrix,
3-mm slice thickness, an increment of 30 mm/s, a rotation time of 1.0 seconds, and a pitch index of
0.9). PET data were reconstructed iteratively (3 iterations, 24 subsets, a gaussian filtering of 2.0 mm
full width at half maximum) with attenuation correction using dedicated standard software (HD-PET,
Siemens Esoft, Siemens Healthineers).
Two experienced, board-certified nuclear medicine physicians (C.L. and J.B.) with access to
relevant clinical data independently rated whole-body and cervical PET/CT imaging results (syngo.via
workstation; Siemens Healthineers). The foci of increased tracer uptake with reference to healthy
tissue and blood pool and/or the presence of morphologic alterations on CT images were recorded as
being positive for tumor involvement. The localization, expansion, and infiltration of osseous
structures, as well as the presence and number of nodal metastases, were recorded for each cervical
lymph node level. Lymph node levels were assessed according to the imaging-based nodal
classification.30,31 Furthermore, whole-body scans were evaluated for distant nodal and organ
metastasis as well as for secondary cancer. Any initial difference in rating between the 2 readers was
resolved via a subsequent consensus reading. If such a difference was present, the maximal and peak
standardized uptake values (SUVs) of the primary tumor, the hottest cervical lymph node, and the
hottest distant metastasis were measured.
Surgery and Specimen Analysis
The operative care of the patients was carried out in line with institutional standards of care and valid
guidelines.19 Surgical treatment consisted of resecting the local tumor and performing a selective
neck dissection (levels I-III; levels I-III and Va; or levels II, III, and Va) or a complete neck dissection of
levels I to V according to the Robbins classification.32 In the case of a negative FDG PET/CT result,
we performed the recommended neck dissection without changing the initial surgical plan. In the
case of positive FDG PET/CT findings on the contralateral side of the tumor, an additional neck
dissection was performed.
Specimens were analyzed by a single experienced pathologist blinded to imaging results. The
assessment was carried out with regard to tumor size, lymph node metastases, lymph vessel and
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venous invasion, perineural infiltration, resection status, and tumor grading according to the TNM
classification of SCC of the oral cavity.13
Statistical Analysis
We aimed to determine the sensitivity, specificity, positive predictive value (PPV), and negative
predictive value (NPV) of FDG PET/CT with a CI of a maximum of ±15%.33 Based on previous
publications on stand-alone FDG-PET33 and an expected dropout rate of 10%, we considered the
enrollment of 150 patients to be sufficient.
Statistical analyses were performed using SPSS, version 24.0 (IBM Corp) and R, version 3.6.1 (R
Foundation for Statistical Computing).43 We assessed sensitivity, specificity, PPV, and NPV of FDG
PET/CT in detecting primary tumors, osseous infiltration, and the presence of cervical lymph node
metastasis on histopathologic analysis. In addition, the diagnostic performance of FDG PET/CT was
calculated for the nodal metastatic involvement of cervical sides and lymph node levels. In 125
patients of the study cohort, these measures were also compared with morphologic imaging via MRI
and contrast-enhanced CT; detailed description of imaging procedures, image analysis, and statistical
analysis are reported in the eMethods in the Supplement. Regarding FDG PET/CT, Spearman ρ
correlational analysis was performed for the association between the uptake of the primary tumor
(maximal and peak SUV) as well as for grading and the tumor size as measured in histopathologic
examination. The maximal and peak SUV values of the primary tumor and the hottest lymph node in
patients rated as positive in FDG PET/CT were furthermore compared via the Mann-Whitney test
regarding the presence and absence of lymph node metastases.
To address the particular clinical relevance of detecting nodal involvement of the contralateral
side, a subgroup analysis was performed in unilaterally located primary tumors. Because metastatic
spread might differ in the tongue, this analysis was performed separately for primary tumors of the
tongue and for tumors of all other primary sites. The diagnostic accuracy of side involvement was
performed for centrally or bilaterally located tumors for both groups. Unilateral tumors (left or right)
were assessed regarding the detection of nodal involvement of the ipsilateral and contralateral neck.
Quantitative values are displayed as mean (SD) or as median and range, as appropriate. Using
2-sided, unpaired t test analysis, findings were considered significant at P < .05.
Results
Of 150 patients, a total of 135 (74 [54.8%] men, 61 [45.2%] women) individuals with a median age of
63 years (range, 23-88 years) met the inclusion criteria and were enrolled in this study; 15 patients
who had cancer other than SCC of the oral cavity were excluded (eFigure in the Supplement). Of the
included participants, 114 patients (84.4%) had a primary tumor located on either the left (n = 60)
or right (n = 54) side, 33 of whom had a unilateral primary tumor of the tongue. Twenty-one patients
(15.6%) had a central or bilateral primary tumor (none with a tongue carcinoma). The primary tumor
sites and localizations are listed in Table 1.
Surgery
All 135 patients underwent primary tumor resection and neck dissection. In 2 cases, the surgeon
decided to extend the lymph node dissection to the contralateral side owing to suspicious findings
noted in the FDG PET/CT. Overall, 229 sides of lymph node dissections (left, right, and bilateral) were
performed: 91 selective neck dissections with extirpation of levels I to III; 46 of levels I to III and Va;
35 of levels II, III, and Va; and 57 complete neck dissections (levels I-III, IV, and V). Levels I, II, and V
were subdivided into a and b. In total, 1226 levels and sublevels were removed.
Histopathologic Analysis and Imaging
Histopathologic analysis revealed a tumor category of T1 in 59 patients (43.7%) and T2 in 41 patients
(30.4%). Four patients had category T3 (3.0%), and 31 had category T4 (23.0%). Tumor grading is
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displayed in Table 1. Ninety-nine patients (73.3%) had no lymph node metastasis (N0), and 36
patients (26.7%) had cervical lymph node metastasis, 18 of whom had a stage of N1 (13.3%) with 1
patient classified as N2a (0.7%), 14 as N2b (10.4%), and 3 as N2c (2.2%). Lymph node metastases
were found in 6 patients (10.2%) with category T1, 16 patients (39.0%) with category T2, in 2
patients (50.0%) with category T3 tumors, and 12 patients (38.7%) with category T4 tumors. In total,
Table 1. Patient Characteristics
Characteristic No. (%)





Localization of primary tumor




Mandibular mucosa 37 (27.4)
Central/lateral 3/34
Maxillary mucosa 16 (11.9)
Central/lateral 1/15































Abbreviation: NA, not available.
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81 of the 5515 assessed lymph nodes (1.5%) contained metastases, which were located across 52
different neck levels (4.2% of 1226 assessed nodal levels). None of the patients investigated showed
distant metastasis. Tissue samples for histopathologic analysis of 9 lesions that were suspicious for
a secondary cancer in FDG PET/CT imaging were obtained in 8 patients. A solid second primary
tumor was confirmed in 6 cases (1 of the glottis, thyroid, lung, and uterus, and 2 of the prostate); 2
patients showed precursor lesions (intraepithelial neoplasia of the colon) and 1 patient had a false-
positive finding in the left tonsil.
In 132 of 135 patients (sensitivity, 97.8%; 95% CI, 95.3%-100.0%), the primary tumor was
detected via FDG PET/CT (maximal SUV: 16.4 [range, 3.2-59.2]; peak SUV: 10.5 [range, 2.4-44.8]). For
31 patients with osseous infiltration, sensitivity was 87.1% (95% CI, 75.3%-98.9%) and specificity was
92.3% (95% CI, 87.2%-97.4%) (PPV: 77.1%; 95% CI, 63.2%-91.1%; NPV: 96.0%; 95% CI,
92.1%-99.8%) (Table 2 and Table 3). Correlational analysis revealed a significant association
between tumor size and uptake (maximal SUV: ρ = 0.62, P < .001; peak SUV: ρ = 0.66; P < .001). The
uptake of primary tumors in patients with cervical lymph node metastases was higher than in
patients without nodal metastases (maximal SUV: 20.8 [range, 6.6.-47.8] vs 11.7 [range, 3.2-59.2];
P < .001; peak SUV: 13.1 [range, 4.8-28.4] vs 6.9 [range, 2.4-44.8]; P < .001). Likewise, the uptake in
the hottest lymph node was higher in patients with cervical metastases than in patients without
lymph node metastasis (maximal SUV: 10.8 [range, 3.6-29.5] vs 5.7 [range, 4.0-8.4]; P < .001; peak
SUV: 6.5 [range, 2.2-24.8] vs 3.4 [range, 2.4-5.4]; P = .004).
Thirty of 36 patients were correctly evaluated as having metastatic nodal involvement
(sensitivity, 83.3%; 95% CI, 71.2%-95.5%; specificity: 84.8%; 95% CI, 77.8%-91.9%; PPV: 66.7%;
95% CI, 52.9%-80.4%; NPV: 93.3%; 95% CI, 88.2%-98.5%). The assessment of a cervical side as
being either positive or negative for 1 or more lymph node metastases was calculated (sensitivity,
73.2%; 95% CI, 59.6%-86.7%; specificity, 89.9%; 95% CI, 85.6%-94.2%; PPV: 61.2%; 95% CI,
47.6%-74.9%; NPV: 93.9%; 95% CI, 90.4%-97.4%). The results of subgroup analysis regarding the
primary tumor site are listed in eTable 1 and eTable 2 in the Supplement. A false-positive evaluation of
cervical sides was more frequent for T4 tumors (32.2%) than for patients with T1 (11.9%) or T2
Table 2. Estimated and True Conditions of FDG PET/CT for Oral Cavity Squamous Cell Carcinoma
Diagnostic question
No.
Total True-positive False-positive False-negative True-negative
Primary tumor 135 132 0 3 0
Osseous infiltration 135 27 8 4 96
Lymph node metastases
Per patient 135 30 15 6 84
Per cervical sides 229 30 19 11 169
Per cervical lymph node level 1226 32 46 20 1128
Abbreviations: CT, computed tomography; FDG, 18-F
fluorodeoxyglucose; PET, positron emission
tomography.






















































Abbreviations: CT, computed tomography; FDG, 18-F
fluorodeoxyglucose; NA, not available; PET, positron
emission tomography.
JAMA Network Open | Surgery Accuracy of 18-F Fluorodeoxyglucose Positron Emission Tomographic/Computed Tomographic Imaging
JAMA Network Open. 2021;4(4):e217083. doi:10.1001/jamanetworkopen.2021.7083 (Reprinted) April 21, 2021 6/12
Downloaded From: https://jamanetwork.com/ by a Universitaet Augsburg User  on 05/18/2021
tumors (7.3%). In all but 1 patient with false-positive findings (Figure, A), histopathologic specimens
contained ulcerating primary tumors and/or additional acute or chronic inflammatory findings (eg,
mucosal inflammation, osteomyelitis, chronic lymphadenitis, and sarcoid-like lesions). The remaining
patient displayed signs of acute tonsillitis on FDG PET/CT. False-negative events occurred in 3.4% of
participants with category T1 tumors, in 14.6% of patients with category T2 tumors, in no patients
with category T3 tumors, and in 9.7% of patients with category T4 tumors. The missed metastases in
false-negatively scored individuals were micrometastases or were less than or equal to a mean size
of 7 mm in diameter (mean [SD], 3.8 [1.7] mm). For the ipsilateral side, true-negative findings existed
for patients with unilateral category T1 or T2 tumors in 93.8% of the cases. This negative predictive
value decreased to 80.0% for patients with category T4 tumors.
A level-based evaluation of nodal involvement (1 lymph node metastasis) correctly identified
1160 of 1226 (94.6%) histopathologically assessed levels as being either positive or negative for
lymph node metastases, resulting in a sensitivity of 61.5% (95% CI, 48.3%-74.8%), specificity of
96.1% (95% CI, 95.0%-97.2%), PPV of 41.0% (95% CI, 30.1%-51.9%), and NPV of 98.3% (95% CI,
97.5%-99.0%) (Table 3).
The comparison of diagnostic measures with MRI and stand-alone CT imaging showed higher
values for sensitivity, specificity, PPV, and NPV of FDG PET/CT throughout all diagnostic possibilities.
However, the sensitivity of FDG PET/CT (98.4%; 95% CI, 96.2%-1.00%) was significantly superior
to that of MRI (69.6%; 95% CI, 61.5%-77.7%) and CT (38.4%; 95% CI, 29.9%-46.9%) only in the
detection of the primary tumor. For the detection of cervical lymph node metastases, FDG PET/CT
showed significantly higher specificity (83.5%; 95% CI, 75.9%-91.1%) than MRI (62.6%; 95% CI,
Figure. Transaxial Computed Tomographic (CT), Positron Emission Tomographic (PET), and Fused PET/CT Images
SCC of the floor of the tongueA
SCC of the floor of the mouthB
Computed tomography Positron emission tomography Fused PET/CT Histopathologic analysis
Computed tomography Positron emission tomography Fused PET/CT Histopathologic analysis
A, Images of a woman aged 71 years with squamous cell carcinoma (SCC) of the floor of
the tongue. Although the CT image is rather unremarkable, PET depicted intense focal
tracer uptake in 2 cervical lymph nodes (arrowheads), which is highly consistent with
metastatic disease. PET findings could be confirmed by histopathologic analysis with the
presence of a keratinizing, moderately to poorly differentiated SCC. Only a small rim of
retained lymph node tissue could be identified (star), and most of the lymph node was
occupied by carcinoma. B, Images of a woman aged 59 years with SCC of the floor of the
mouth (star). Both the CT and PET images depicted bilateral, enlarged/hypermetabolic
lymph nodes that are suspicious for nodal metastases (arrowheads). However,
histopathologic analysis revealed only inflammatory and reactive changes with
prominent reactive secondary follicles of the lymph node. There was no evidence of
cancer. Hemotoxylin-eosin, original magnification ×20 in histopathologic analysis.
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52.7%-72.6%), and CT (67.0%; 95% CI, 57.4%-76.7%), as well as greater PPV (FDG PET/CT: 65.1%;
95% CI, 50.9%-79.4%; MRI: 41.4%; 95% CI, 28.7%-54.1%; CT: 43.4%; 95% CI, 30.1%-56.7%) and
NPV (FDG PET/CT: 92.7%; 95% CI, 87.0%-98.3%; MRI: 85.1%; 95% CI, 76.5%-93.6%; CT: 84.7%;
95% CI, 76.4%-93.0%) (Table 4; eTable 3 in the Supplement). No adverse events occurred during
FDG PET/CT imaging.
Discussion
In this cohort of 135 patients with newly diagnosed SCC of the oral cavity, FDG PET/CT was able to
detect the primary tumor in 97.8% of the cases, thereby confirming the high sensitivity of FDG
PET/CT and its superiority to stand-alone CT and MRI.34 All nondetected primary tumors occurred in
patients with category T1 cancer with a primary tumor extension of less than or equal to 6 mm—a
size that lies at the limit of PET resolution.35
The presence of cervical lymph node metastases is one of the most important prognostic
factors in SCC of the oral cavity,5-8 and the accurate staging of nodal involvement is necessary. In this
cohort, local lymph node metastases were present in 26.7% of the patients, with increasing
frequency in higher T categories.36 Regarding the detection of locoregional metastases, FDG PET/CT
demonstrated good sensitivity (83.3%) and specificity (84.8%), as well as high NPV (93.3%), all of
which lay within the range of previous reports24,27,28 and were higher than the diagnostic measures
of CT and MRI. Regarding side discrimination of locoregional metastasis, FDG PET/CT showed high
sensitivity (73.2%) and specificity (89.9%) in this cohort. All false-negative findings, which were
present in 11 (8.1%) of 135 patients, measured less than or equal to 7 mm in lymph node diameter and
were predominantly present on the ipsilateral side of the tumor. In subgroup analysis for unilateral
primary tumors, FDG PET/CT indicated true-negative lymph node status for the contralateral side in
97.3% of all cases.
False-positive findings were less frequent on the contralateral side and were likely caused by
reactive processes in the oral cavity that are related to either ulcerating tumor growth, local tumor
infiltration, or additional acute or chronic inflammatory disease. The difficulty in differentiating
inflammatory processes from tumor metabolism with FDG PET/CT is well known,37 although tracer
uptake was significantly higher for true-positive than for false-positive ratings in our study.
Level-based evaluation of the neck might help to optimize preoperative planning. Furthermore,
additional information on possible skip metastases can alter the regimen of performed neck
Table 4. Comparison of Diagnostic Accuracy of FDG PET/CT, MRI, and CT in 125 Patients of Study Cohort
Compared modalities
%
Sensitivity Specificity Positive predictive value Negative predictive value
Primary tumor
FDG PET/CT vs MRI 98.4 vs 69.6a NA NA NA
FDG PET/CT vs CT 98.4 vs 38.4a NA NA NA
Osseous infiltration
FDG PET/CT vs MRI 86.7 vs 73.3 91.6 vs 90.5 76.5 vs 71.0 95.6 vs 91.5
FDG PET/CT vs CT 86.7 vs 69.0b 91.6 vs 90.5 76.5 vs 69.0 95.6 vs 89.6b
Lymph node metastases
FDG PET/CT vs MRI 82.4 vs 70.6 83.5 vs 62.6a 65.1 vs 41.4a 92.7 vs 85.1b
FDG PET/CT vs CT 82.4 vs 67.6 83.5 vs 67.0c 65.1 vs 43.4a 92.7 vs 84.7b
Lymph node metastases in cervical sides
FDG PET/CT vs MRI 73.6 vs 63.1 89.1 vs 74.3a 59.6 vs 34.8a 94.0 vs 90.3b
FDG PET/CT vs CT 73.6 vs 57.9 89.1 vs 76.6a 59.6 vs 34.9a 94.0 vs 89.3b
Lymph node metastases in cervical lymph node levels
FDG PET/CT vs MRI 58.3 vs 45.8 95.8 vs 92.2a 37.8 vs 20.6a 98.1 vs 97.5b
FDG PET/CT vs CT 58.3 vs 39.6b 95.8 vs 91.8a 37.8 vs 17.6a 98.1 vs 97.2b
Abbreviations: CT, computed tomography; FDG, 18-F
fluorodeoxyglucose; NA, not available; PET, positron
emission tomography.
a P < .001.
b P < .05.
c P < .01.
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dissection.36 In our study, 94.6% of histopathologically assessed levels were correctly identified as
being either positive or negative for lymph node metastases.
This study also expands on earlier findings on the high NPV of FDG PET/CT28; however, those
findings were derived from a preselected cohort with head and neck SCC and clinically N0 necks after
MRI, whereas we investigated a homogeneous cohort of patients with SCC of the oral cavity without
the exclusion of necks with lymph node involvement after imaging with MRI. This procedure enables
a better estimation of diagnostic measures and a direct comparison with MRI and stand-alone
diagnostic, contrast-enhanced CT. Our results suggest that FDG PET/CT imaging is superior (Table 4,
Figure, B) and that its clinical preoperative use in assessing cervical lymph node metastases could
increase specificity, PPV, and NPV. The high and superior NPV for the respective cervical sides
(94.0%) and levels (98.3%) should be considered before surgery to optimize neck dissection, which
is important because the dissection of lymph node metastases leads to an increase in the likelihood
of survival,38 whereas elective neck dissection is accompanied by poorer health-related quality of
life.20,39-41 A more reliable estimation of lymphogenic metastases thus results in increased quality
of life.
Although separate analyses of unilateral tongue carcinoma have shown poorer results than at
other primary sites for ipsilateral lymph node involvement (sensitivity: 60.0%; specificity: 81.0%),
correct estimation of the nodal stage on the contralateral side was possible in all 23 patients
(sensitivity: 100.0%; specificity: 100.0%). Because only 1 patient had contralateral lymph node
metastases, these promising results must be critically reviewed. Further investigations with a larger
group size are needed for a more conclusive statement.
An additional advantage of whole-body FDG PET/CT over cervical CT and MRI is its reliable
screening results for distant metastases or secondary cancer, both of which result in a necessary
change to the therapeutic regimen.9 In this cohort, none of the patients showed distant metastasis,
but a solid second primary tumor or malignant precursor lesion was confirmed in 8 of 9 cases with
suspicious image findings. Whole-body FDG PET/CT might either enable early detection at a
precancerous/curable stage or prevent surgical procedures for SCC of the oral cavity in the presence
of an unknown advanced second primary tumor.
Limitations
This study had limitations. Considering that metastasis could be proven in 26.7% of the patients,
73.3% of the study participants experienced a risk of overtreatment. However, because all patients
underwent elective neck dissection irrespective of imaging findings, this study does not reveal the
actual value of FDG PET/CT in patients who, for example, have received a PET-guided elective neck
dissection without removing the contralateral cervical lymph nodes.42 Further prospective studies
are needed to directly evaluate the influence of whole-body FDG PET/CT on patient management
and follow-up.
Conclusions
The results of this study suggest that combined FDG PET/CT is a valuable diagnostic tool in the
preoperative staging of SCC of the oral cavity. Use of FDG PET/CT was associated with a high NPV and
was superior to stand-alone morphologic imaging.
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